Ossium Health, Inc. announced that the US FDA has accepted its Investigational New Drug application for OSSM-001, an MSC product, for the treatment of refractory perianal fistulas in patients with Crohn’s disease.
[Ossium Health, Inc. (Business Wire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
